{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+or+equivalent", "query": { "intervention": "Methylprednisolone or equivalent" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 78, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Methylprednisolone+or+equivalent&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T15:56:59.229Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04544436", "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Antihistamine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 864, "start_date": "2020-11-26", "completion_date": "2028-08-31", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 25, "location_summary": "Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544436" }, { "nct_id": "NCT01238536", "title": "Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Spinal Stenosis", "Low Back Pain" ], "interventions": [ { "name": "Epidural steroid with local anesthetic injection", "type": "PROCEDURE" }, { "name": "Epidural local anesthetic injection", "type": "PROCEDURE" }, { "name": "Epidural steroid injection", "type": "DRUG" }, { "name": "Epidural local anesthetic injection", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 400, "start_date": "2011-04", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-12-13", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 10, "location_summary": "Redwood City, California • Roseville, California • Denver, Colorado + 7 more", "locations": [ { "city": "Redwood City", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01238536" }, { "nct_id": "NCT02061800", "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia (CML)", "Acute Myelogenous Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Juvenile Myelomonocytic Leukemia (JMML)", "Acute Lymphoblastic Leukemia (ALL)", "Lymphoma (Hodgkin's and Non-Hodgkin's)" ], "interventions": [ { "name": "CliniMACS CD34+ Reagent System", "type": "DEVICE" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Diane George", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 14, "start_date": "2013-06-03", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061800" }, { "nct_id": "NCT02550652", "title": "A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Mycophenolate Mofetil/Mycophenolic Acid", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 126, "start_date": "2015-11-13", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 7, "location_summary": "La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Great Neck", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02550652" }, { "nct_id": "NCT02176031", "title": "Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2015-01", "completion_date": "2019-02", "has_results": true, "last_update_posted_date": "2020-04-17", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02176031" }, { "nct_id": "NCT01858922", "title": "Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "ABVE-PC", "type": "DRUG" }, { "name": "DECA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2012-12-19", "completion_date": "2019-08-12", "has_results": false, "last_update_posted_date": "2024-01-12", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01858922" }, { "nct_id": "NCT06598332", "title": "5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Graft-Versus-Host Disease(GVHD)" ], "interventions": [ { "name": "5-Azacytidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2025-08", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06598332" }, { "nct_id": "NCT02462252", "title": "Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aplastic Anemia", "Hypoplastic Myelodysplastic Syndrome" ], "interventions": [ { "name": "BL-8040", "type": "DRUG" }, { "name": "horse anti-thymocyte globulin (hATG)", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2015-10", "completion_date": "2020-11", "has_results": false, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02462252" }, { "nct_id": "NCT03139604", "title": "GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft-versus-host Disease (GVHD)" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 439, "start_date": "2017-07-19", "completion_date": "2020-07-13", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 49, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 38 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03139604" }, { "nct_id": "NCT01217697", "title": "Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Prostate Neoplasms", "Genital Neoplasms, Male", "Urogenital Neoplasms", "Genital Diseases, Male" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone\\Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2017-03-24", "last_synced_at": "2026-09-25T15:56:59.229Z", "location_count": 157, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 154 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217697" } ] }